Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GoldenExo in Adult Type 2 Diabetes Mellitus
NCT07693036Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Peking University First Hospital. Primary endpoint: Change in Glycated Hemoglobin at 8 weeks. Started Jun 2026; status: recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07693036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693036.